Boehringer Ingelheim and Philogen, a Swiss biotechnology company, will collaborate on investigating treatment approaches for acute myeloid leukemia (AML). As part of the collaborative effort, the partners have agreed on an exploratory trial investigating novel immunotherapy concepts for relapsed AML patients.

Further details about the planned clinical trial will be communicated at a forthcoming scientific meeting. Financial details will not be communicated.

Source: Boehringer Ingelheim